Orchard Therapeutics plc Quarterly Operating Income (Loss) in USD from Q1 2018 to Q3 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Orchard Therapeutics plc quarterly/annual Operating Income (Loss) history and growth rate from Q1 2018 to Q3 2023.
  • Orchard Therapeutics plc Operating Income (Loss) for the quarter ending September 30, 2023 was -$21.6M, a 15.2% increase year-over-year.
  • Orchard Therapeutics plc Operating Income (Loss) for the twelve months ending September 30, 2023 was -$102M, a 22.7% increase year-over-year.
  • Orchard Therapeutics plc annual Operating Income (Loss) for 2022 was -$127M, a 9.5% increase from 2021.
  • Orchard Therapeutics plc annual Operating Income (Loss) for 2021 was -$140M, a 10.5% increase from 2020.
  • Orchard Therapeutics plc annual Operating Income (Loss) for 2020 was -$157M, a 9.2% increase from 2019.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2023 -$102M -$21.6M +$3.86M +15.2% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-13
Q2 2023 -$106M -$22.6M +$9.89M +30.5% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-10
Q1 2023 -$116M -$26.3M +$11.3M +30.1% Jan 1, 2023 Mar 31, 2023 10-Q 2023-05-15
Q4 2022 -$127M -$31.6M +$4.82M +13.2% Oct 1, 2022 Dec 31, 2022 10-K 2023-03-14
Q3 2022 -$132M -$25.5M +$7.45M +22.6% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 -$139M -$32.4M +$3.56M +9.9% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 -$143M -$37.6M -$2.49M -7.11% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 -$140M -$36.4M +$2.46M +6.32% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-14
Q3 2021 -$143M -$32.9M -$6.62M -25.2% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 -$136M -$36M +$10.8M +23.1% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 -$147M -$35.1M +$9.9M +22% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 -$157M -$38.9M +$10.2M +20.7% Oct 1, 2020 Dec 31, 2020 10-K 2021-03-02
Q3 2020 -$167M -$26.3M +$15.1M +36.5% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 -$182M -$46.8M +$7.33M +13.5% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-04
Q1 2020 -$190M -$45M -$16.7M -59% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-13
Q4 2019 -$173M -$49M -$20.2M -70% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-02
Q3 2019 -$153M -$41.4M -$7.32M -21.5% Jul 1, 2019 Sep 30, 2019 10-K 2021-03-02
Q2 2019 -$145M -$54.2M +$104M +65.8% Apr 1, 2019 Jun 30, 2019 10-K 2021-03-02
Q1 2019 -$250M -$28.3M -$14.6M -106% Jan 1, 2019 Mar 31, 2019 10-K 2021-03-02
Q4 2018 -$235M -$28.8M Oct 1, 2018 Dec 31, 2018 10-K 2020-02-27
Q3 2018 -$34.1M Jul 1, 2018 Sep 30, 2018 10-K 2020-02-27
Q2 2018 -$158M Apr 1, 2018 Jun 30, 2018 10-K 2020-02-27
Q1 2018 -$13.7M Jan 1, 2018 Mar 31, 2018 10-K 2020-02-27
* An asterisk sign (*) next to the value indicates that the value is likely invalid.